| Group A | Group B | Total |
---|---|---|---|
Number of patients | 22 | 18 | 40 |
Gender | Â | Â | Â |
Male | 14 | 7 | 21 |
Female | 8 | 11 | 19 |
Age at IA diagnosis | Â | Â | Â |
Median (years) | 11.94 | 8.64 | 11.05 |
Range | (1.3–17.2) | (1.18–17.9) | (1.18–17.9) |
Underlying disease | Â | Â | Â |
ALL-AML | 15 | 13 | 28 |
CML | 2 | 0 | 2 |
NHL+HD | 2 | 2 | 4 |
MDS | 2 | 1 | 3 |
Non-malignant diseases | 1 | 2 | 3 |
IA after relapse of underlying disease | 9 | 5 | 14 |
Interval from relapse to IA (days) | Â | Â | Â |
   Median | 69 | 105 | 74 |
   Range | (18–174) | (7–261) | (7–261) |
IA after allogeneic HSCT | 7 | 6 | 13 |
   Source of SC |  |  |  |
BM | 7 | 4 | 11 |
PB | / | 1 | 1 |
CB | / | 1 | 1 |
Interval from HSCT to IA (days) | Â | Â | Â |
   Median | 14 | 15 | 14 |
   Range | (4–308) | (0–54) | (0–308) |
IA after diagnosis of underlying disease | 6 | 7 | 13 |
Interval from diagnosis to IA (days) | Â | Â | Â |
   Median | 115 | 46 | 74 |
   Range | (15–318) | (13–76) | (13–318) |
Remission status of underlying disease * | 21 | 16 | 37 |
Complete remission | 6 | 7 | 13 |
Other status | 15 | 9 | 24 |